United’s oral prostacyclin walks to FREEDOM as analysts await longer trial
This article was originally published in Scrip
Executive Summary
United Therapeutics' Phase III FREEDOM-M study for its twice-daily oral form of prostacyclin, treprostinil, in pulmonary arterial hypertension (PAH) met its primary endpoint in a 12-week trial – improving patients' walking ability on a six-minute walk distance test. However, analysts are more interested in the United’s other trial, FREEDOM-C2, which takes a longer look at more severly affected patients.